HRP20211949T1 - Derivat pirazol primidina i njegove uporabe - Google Patents
Derivat pirazol primidina i njegove uporabe Download PDFInfo
- Publication number
- HRP20211949T1 HRP20211949T1 HRP20211949TT HRP20211949T HRP20211949T1 HR P20211949 T1 HRP20211949 T1 HR P20211949T1 HR P20211949T T HRP20211949T T HR P20211949TT HR P20211949 T HRP20211949 T HR P20211949T HR P20211949 T1 HRP20211949 T1 HR P20211949T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- branched
- straight
- alkyl
- compound
- Prior art date
Links
- KEUDMLLLHGLIGH-UHFFFAOYSA-N 1h-pyrazole;pyrimidine Chemical class C=1C=NNC=1.C1=CN=CN=C1 KEUDMLLLHGLIGH-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 15
- 150000004820 halides Chemical class 0.000 claims 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 14
- 229910052799 carbon Inorganic materials 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 11
- 229920006395 saturated elastomer Polymers 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 150000001408 amides Chemical class 0.000 claims 6
- 150000002148 esters Chemical class 0.000 claims 6
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 3
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 230000003211 malignant effect Effects 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 230000006023 anti-tumor response Effects 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 238000002619 cancer immunotherapy Methods 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562200846P | 2015-08-04 | 2015-08-04 | |
| US201562268750P | 2015-12-17 | 2015-12-17 | |
| EP16753709.1A EP3331877B1 (en) | 2015-08-04 | 2016-08-04 | Pyrazole pyrimidine derivative and uses thereof |
| PCT/IL2016/050852 WO2017021969A1 (en) | 2015-08-04 | 2016-08-04 | Pyrazole pyrimidine derivative and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211949T1 true HRP20211949T1 (hr) | 2022-03-18 |
Family
ID=56738143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211949TT HRP20211949T1 (hr) | 2015-08-04 | 2016-08-04 | Derivat pirazol primidina i njegove uporabe |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10376511B2 (enExample) |
| EP (1) | EP3331877B1 (enExample) |
| JP (1) | JP7083309B2 (enExample) |
| KR (1) | KR102698366B1 (enExample) |
| CN (1) | CN108137562B (enExample) |
| AU (2) | AU2016304464B2 (enExample) |
| CA (1) | CA2994644A1 (enExample) |
| CY (1) | CY1124898T1 (enExample) |
| DK (1) | DK3331877T3 (enExample) |
| ES (1) | ES2901349T3 (enExample) |
| HR (1) | HRP20211949T1 (enExample) |
| HU (1) | HUE057607T2 (enExample) |
| IL (1) | IL257282B (enExample) |
| LT (1) | LT3331877T (enExample) |
| MX (1) | MX384172B (enExample) |
| PL (1) | PL3331877T3 (enExample) |
| PT (1) | PT3331877T (enExample) |
| RS (1) | RS62728B1 (enExample) |
| RU (1) | RU2735522C2 (enExample) |
| SI (1) | SI3331877T1 (enExample) |
| SM (1) | SMT202100720T1 (enExample) |
| WO (1) | WO2017021969A1 (enExample) |
| ZA (1) | ZA201800671B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20211949T1 (hr) * | 2015-08-04 | 2022-03-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Derivat pirazol primidina i njegove uporabe |
| NZ755447A (en) | 2017-02-01 | 2023-05-26 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| AU2019219678A1 (en) * | 2018-02-08 | 2020-08-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use |
| TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| CN114423752B (zh) * | 2019-06-03 | 2025-06-24 | 耶路撒冷希伯来大学伊萨姆研究发展公司 | 吡唑化合物的非吸湿性结晶盐和其药物组合物与用途 |
| WO2021000957A1 (zh) * | 2019-07-04 | 2021-01-07 | 北京国鸿生物医药科技有限公司 | 一种杂环化合物、其药物组合物及用途 |
| MX2022001940A (es) | 2019-08-14 | 2022-05-10 | Incyte Corp | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2. |
| CN119930610A (zh) | 2019-10-11 | 2025-05-06 | 因赛特公司 | 作为cdk2抑制剂的双环胺 |
| US20230047732A1 (en) * | 2020-01-13 | 2023-02-16 | Biotheryx, Inc. | Pyrazolylpyrimidines and use thereof |
| WO2021155050A1 (en) * | 2020-01-29 | 2021-08-05 | Biotheryx, Inc. | Kinase modulators, pharmaceutical compositions, and therapeutic applications |
| JP7729832B2 (ja) * | 2020-03-26 | 2025-08-26 | ヤンセン ファーマシューティカ エヌ．ベー． | モノアシルグリセロールリパーゼ調節因子としてのアリールピペリジン |
| AU2022242818A1 (en) * | 2021-03-24 | 2023-10-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Pyrazolylpyrimidines for treating malignant solid tumor |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11752151B2 (en) * | 2021-07-12 | 2023-09-12 | Buddhist Tzu Chi Medical Foundation | Method for enhancing hair growth |
| US20230053307A1 (en) * | 2021-07-19 | 2023-02-16 | Buddhist Tzu Chi Medical Foundation | Method for preventing or treating skin disorders and conditions |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| WO2025199440A1 (en) * | 2024-03-21 | 2025-09-25 | Edgewood Oncology | Methods of treating liposarcoma using a pyrazole compound |
| WO2025199434A1 (en) * | 2024-03-21 | 2025-09-25 | Edgewood Oncology | Methods of treating breast cancer using a pyrazole compound |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE407132T1 (de) | 2000-12-05 | 2008-09-15 | Vertex Pharma | Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen |
| JP4316893B2 (ja) | 2001-05-16 | 2009-08-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｓｒｃおよび他のプロテインキナーゼのインヒビター |
| GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| RU2373197C2 (ru) * | 2004-03-30 | 2009-11-20 | Тайсо Фармасьютикал Ко., Лтд. | Пиримидиновые производные, обладающие активностью в отношении мсн |
| JP2007145819A (ja) | 2005-10-28 | 2007-06-14 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| JP2009538352A (ja) | 2006-05-26 | 2009-11-05 | アストラゼネカ アクチボラグ | 細胞増殖を阻害するための薬剤としての２−カルボシクロアミノ−４−イミダゾリルピリミジン類 |
| CA2707989A1 (en) | 2007-12-07 | 2009-06-11 | Novartis Ag | Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases |
| ES2629690T3 (es) | 2011-11-04 | 2017-08-14 | Jasco Pharmaceuticals, LLC | Inhibidores de aminopirimidina quinasa |
| KR20160092991A (ko) | 2013-09-27 | 2016-08-05 | 님버스 아이리스 인코포레이티드 | Irak 억제제 및 이의 용도 |
| US10047070B2 (en) * | 2013-10-18 | 2018-08-14 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
| HRP20211949T1 (hr) * | 2015-08-04 | 2022-03-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Derivat pirazol primidina i njegove uporabe |
| NZ755447A (en) * | 2017-02-01 | 2023-05-26 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer |
| AU2019219678A1 (en) | 2018-02-08 | 2020-08-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use |
-
2016
- 2016-08-04 HR HRP20211949TT patent/HRP20211949T1/hr unknown
- 2016-08-04 WO PCT/IL2016/050852 patent/WO2017021969A1/en not_active Ceased
- 2016-08-04 SI SI201631426T patent/SI3331877T1/sl unknown
- 2016-08-04 LT LTEPPCT/IL2016/050852T patent/LT3331877T/lt unknown
- 2016-08-04 CA CA2994644A patent/CA2994644A1/en active Pending
- 2016-08-04 CN CN201680059148.XA patent/CN108137562B/zh active Active
- 2016-08-04 HU HUE16753709A patent/HUE057607T2/hu unknown
- 2016-08-04 KR KR1020187006128A patent/KR102698366B1/ko active Active
- 2016-08-04 AU AU2016304464A patent/AU2016304464B2/en active Active
- 2016-08-04 SM SM20210720T patent/SMT202100720T1/it unknown
- 2016-08-04 ES ES16753709T patent/ES2901349T3/es active Active
- 2016-08-04 PL PL16753709T patent/PL3331877T3/pl unknown
- 2016-08-04 RS RS20211558A patent/RS62728B1/sr unknown
- 2016-08-04 DK DK16753709.1T patent/DK3331877T3/da active
- 2016-08-04 MX MX2018001395A patent/MX384172B/es unknown
- 2016-08-04 PT PT167537091T patent/PT3331877T/pt unknown
- 2016-08-04 JP JP2018525826A patent/JP7083309B2/ja active Active
- 2016-08-04 EP EP16753709.1A patent/EP3331877B1/en active Active
- 2016-08-04 US US15/748,536 patent/US10376511B2/en active Active
- 2016-08-04 RU RU2018107668A patent/RU2735522C2/ru active
-
2018
- 2018-01-31 ZA ZA2018/00671A patent/ZA201800671B/en unknown
- 2018-01-31 IL IL257282A patent/IL257282B/en active IP Right Grant
-
2019
- 2019-08-12 US US16/538,550 patent/US10960003B2/en active Active
-
2021
- 2021-02-10 AU AU2021200839A patent/AU2021200839A1/en not_active Abandoned
- 2021-03-29 US US17/215,959 patent/US11925641B2/en active Active
- 2021-12-21 CY CY20211101124T patent/CY1124898T1/el unknown
-
2024
- 2024-02-05 US US18/432,931 patent/US12514859B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211949T1 (hr) | Derivat pirazol primidina i njegove uporabe | |
| HRP20231619T1 (hr) | Derivati kamptotecina | |
| RU2475484C2 (ru) | Полициклические производные индазола и их применение в качестве ингибиторов erk для лечения рака | |
| HRP20211124T1 (hr) | TETRAHIDRO-1H-PIRIDO[3,4-b]INDOL ANTI-ESTROGENI LIJEKOVI | |
| PE20191540A1 (es) | DERIVADOS DE PIRROLO [1,2-b] PIRIDAZINA | |
| HRP20241540T1 (hr) | Pirolotriazinski spojevi koji djeluju kao inhibitor mnk | |
| JP2018525441A5 (enExample) | ||
| HRP20202073T1 (hr) | Derivati n-(fenilsulfonil)benzamida kao bcl-2 inhibitori | |
| ME02583B (me) | Jedinjenja pirolidinil uree, pirolidinil tiouree i pirolidinil guanidina kao inhibitori trka kinaze | |
| CO6210819A2 (es) | Agonistas de adrenoreceptores alfa2c funcionalmente selectivos | |
| AR088320A1 (es) | Derivados de isoindolinona y pirrolopiridinona como inhibidores de akt | |
| HRP20140195T1 (hr) | Supstituirani derivati triazolopiridazina | |
| RU2016118768A (ru) | Композиции, пригодные для лечения расстройств, связанных с kit | |
| HRP20240101T1 (hr) | Supstituirani heterociklil derivati kao cdk inhibitori | |
| HRP20160350T1 (hr) | Heterociklički spojevi i njihove uporabe | |
| AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
| HRP20170750T1 (hr) | Derivati benzimidazolona kao inhibitori bromodomena | |
| HRP20140409T1 (hr) | Derivat imidazola sa strukturom prolinskog prstena | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| HRP20161478T1 (hr) | Inhibitori protein kinaze (varijante), njihova upotreba za liječenje neuroloških bolesti, kao i farmaceutski pripravak koji se na njima temelji | |
| JP2017503833A5 (enExample) | ||
| HRP20230342T1 (hr) | Kationski lipid koji se može ionizirati za isporuku rna | |
| HRP20170217T1 (hr) | Fuzinirani heterociklički spojevi kao inhibitori protein kinaze | |
| RU2019127038A (ru) | N1-(4-(5-(циклопропилметил)-1-метил-1h-пиразол-4-ил)пиридин-2-ил)циклогексан-1,4-диаминовые производные и родственные соединения в качестве ингибиторов сk1 и/или irak1 для лечения рака | |
| MX344276B (es) | Compuesto de piperidina novedoso o sal del mismo. |